PharmExec11h
Mim8 Demonstrates Promising Results in Pediatric Patients with Hemophilia A
Data from the Phase III FRONTIER3 trial found that 98% of caregivers prefer Mim8 for hemophilia A over other treatments.
PharmExec12h
The LIBERTAS Study: Q&A with Biljana Naumovic of J&J
Biljana Naumovic discusses how a new study attempted to bring in patients from underserved communities.
PharmExec12h
Main Contributors of Social Media Uncertainty & Distrust
In this part of his Pharmaceutical Executive video interview, Ian Baer, Founder & CEO of Sooth, explores the contributing ...
PharmExec12h
Potential Risks of Relying on Open-Access AI Models
In this Pharmaceutical Executive video interview, Edoardo Madussi, Head of Business Development, Intelligencia AI identifies ...